Studying Low Blood Cell Counts After CAR-T Therapy in Myeloma or Lymphoma
Studies gene changes linked to low blood counts after CAR-T in myeloma patients.
Plain-language title generated from the registry record
Registry title: Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Key facts
- Where
- Albert Lea, Eau Claire, Jacksonville, La Crosse, Mankato, Rochester, and Scottsdale, United StatesSee the 7 sites
Where in United States
- Mayo Clinic Health System in Albert LeaAlbert Lea, United StatesTaking people
- Mayo Clinic Health System-Eau Claire ClinicEau Claire, United StatesTaking people
- Mayo Clinic in FloridaJacksonville, United StatesTaking people
- Mayo Clinic Health System-Franciscan HealthcareLa Crosse, United StatesTaking people
- Mayo Clinic Health System MankatoMankato, United StatesTaking people
- Mayo Clinic in RochesterRochester, United StatesTaking people
- Mayo Clinic in ArizonaScottsdale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06630104
- Record updated
- 1 October 2026
- Original description
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.Read full original descriptionShow less
MC230818 Understanding the Mechanisms of Clonal and Non-Clonal Cytopenia Following CAR-T Therapy
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.
Inclusion: Age ≥ 18 years; Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined in International Myeloma Working Group (IMWG) criteria or a CD19+ lymphoproliferative disorder (LPD) as defined by 2016 World Health Organization (WHO) classification; Provide written informed consent; Willingness to provide mandatory bone marrow aspirate specimens for correlative research. All bone marrow aspirate samples are collected during a clinical procedure; Willingness to provide mandatory hair follicle or skin punch biopsy specimens (skin punch biopsy specimens will be obtained from Mayo Clinic Rochester patients only) for correlative research; Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study); Willingness to provide mandatory saliva or buccal swab sample for correlative research.
Exclusion: Ineligible for CAR-T therapy; Patients diagnosed with myeloid neoplasm before CAR-T therapy.